FOLH1 and neoplasm: Although it has recently been demonstrated in patients that the uptake of [177Lu]Lu-rhPSMA-7.3 in tumor lesions was on average 2- to 3-fold higher than that of [177Lu]Lu-PSMA I&T, the slower clearance resulted in a comparatively higher dose to the kidney as the organ at risk (14).